Onkure Therapeutics Inc (OKUR)

May 05, 2025

Renaissance Technologies LLC Invests $408,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

May 05, 2025

May 03, 2025

OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages - Defense World

May 03, 2025

May 02, 2025

Geode Capital Management LLC Makes New $659,000 Investment in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

May 02, 2025

May 02, 2025

Q1 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World

May 02, 2025

Apr 30, 2025

OnKure Therapeutics initiated with an Outperform at Evercore ISI - TipRanks

Apr 30, 2025

Apr 30, 2025

Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating - marketscreener.com

Apr 30, 2025

Apr 30, 2025

Evercore ISI starts OnKure stock with Outperform rating - Investing.com

Apr 30, 2025

Apr 30, 2025

Evercore ISI starts OnKure stock with Outperform rating By Investing.com - Investing.com India

Apr 30, 2025

Apr 28, 2025

OKUR stock touches 52-week low at $2.49 amid market challenges - Investing.com

Apr 28, 2025

Apr 10, 2025

OnKure Therapeutics CEO sells $2,569 in stock - Investing.com Australia

Apr 10, 2025

Apr 08, 2025

OnKure Therapeutics CFO sells $9,177 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

OnKure Therapeutics CEO sells $2,569 in stock By Investing.com - Investing.com India

Apr 08, 2025

Apr 08, 2025

OnKure Therapeutics CFO sells $9,177 in stock - Investing.com

Apr 08, 2025

Apr 05, 2025

OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

OKUR stock touches 52-week low at $3.39 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Mar 29, 2025

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st

Mar 29, 2025

Mar 28, 2025

OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 21, 2025

Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World

Mar 21, 2025

Mar 20, 2025

OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 18, 2025

H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia

Mar 18, 2025

Mar 18, 2025

Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks

Mar 18, 2025

Mar 18, 2025

H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India

Mar 18, 2025

Mar 18, 2025

Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks

Mar 18, 2025

Mar 16, 2025

Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Mar 16, 2025

Mar 15, 2025

OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Onkure discovers new PI3Kα inhibitors - BioWorld Online

Mar 14, 2025

Mar 14, 2025

What is Lifesci Capital’s Estimate for OKUR FY2025 Earnings? - Defense World

Mar 14, 2025

Mar 12, 2025

Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects - TipRanks

Mar 12, 2025

Mar 12, 2025

Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely? - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer - Defense World

Mar 12, 2025

Mar 12, 2025

OnKure Therapeutics Reports Progress and Financials - TipRanks

Mar 12, 2025

Mar 11, 2025

OnKure boosts R&D spending with cancer trial underway - BizWest

Mar 11, 2025

Mar 11, 2025

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 11, 2025

Mar 11, 2025

Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating - Marketscreener.com

Mar 11, 2025

Mar 10, 2025

OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer - TipRanks

Mar 10, 2025

Mar 10, 2025

OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c) - TipRanks

Mar 10, 2025

Mar 10, 2025

OnKure Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 10, 2025

Mar 10, 2025

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Mar 10, 2025

Mar 04, 2025

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences - GlobeNewswire

Mar 04, 2025

Mar 04, 2025

OnKure Therapeutics (NASDAQ:OKUR) Trading Down 4.7% – Time to Sell? - Defense World

Mar 04, 2025

Feb 11, 2025

FY2025 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World

Feb 11, 2025

Jan 31, 2025

Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com

Jan 31, 2025

Jan 31, 2025

After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews

Jan 31, 2025

Jan 29, 2025

Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - Nasdaq

Jan 29, 2025

Jan 29, 2025

Jones Trading sets OnKure stock Buy rating, $32 target - MSN

Jan 29, 2025